Peter Tsai is the founder, Chairman, and a member of the Board of Directors of OEP Group. He oversees the Corporate Social Responsibility, People and Talent Management, and Business Development teams.
Under Peter’s leadership, OEP has grown from a leading regional distributor to a full-scale pharmaceutical company with over 1000 employees, operations in 10 countries, world-class R&D and manufacturing capabilities, and a diverse product portfolio.
He is an active participant in Taiwan’s pharmaceutical industry policy making, including serving as President of the Taiwan Pharmaceutical Industry Technology Development Center, board member of the Institute for Biotechnology and Medicine Industry (IBMI), and executive director of the Biopharmaceutical Manufacturers Association.
Peter began his career as a top salesman for Pfizer’s Upjohn in Taiwan, helping it become the no. 2 pharmaceutical company in the country. He launched OEP to have an even greater impact as the commercial distributor of choice for partners such as Sanofi’s Rhône-Poulenc and Pierre Fabre, among many others.
Peter holds a B.A. in Chinese literature from Soochow University, Taiwan’s first private university.
Calvin Tsai is the Chief Executive Officer of OEP Group, and a member of the Board of Directors.
Since he joined OEP in 2007, Calvin has held several leadership roles, serving as General Manager of Hong Kong, and Business Development and Chief Commercial Officer. During his 13 years at OEP, Calvin has expanded the company’s footprint into southeast Asia, securing licensing deals for Chiesi’s respiratory products, and UCB’s CNS portfolio. He also led the expansion of sales into the U.S. market with five successful ANDAs, including a Paragraph IV filing, and oversaw the planning and building of the company’s high-potency injectable plant.
Calvin previously worked for Deloitte & Touche, and Elan Pharmaceuticals. He obtained his B.A. from the University of California, Riverside.
Wen-Chin Tsai, Ph.D. is Head of the Science and Technology Division. He oversees the medical affairs, research and development, analytical research, and project management of OEP’s product portfolio.
He has 30 years of experience in pharmaceutical development, including in the chemistry, manufacturing and controls of small molecules, oligonucleotides, and pegylated proteins in drug substances and drug products; the preparation of these materials for IND, CTA, NDA, MAA and BLA regulatory filings; and the monitoring of two cGMP manufacturing sites for the production of protein (enzyme) drug substances and drug products.
Prior to OEP Pharma, Wen-Chin held several scientific leadership positions, serving as Senior Vice President of Quality Assurance and Quality Control at DesigneRx Pharmaceuticals, Inc.; Executive Director of Regulatory CMC and Pharmaceutical Development for Polaris Pharmaceuticals, Inc.; and Director of Analytical Development & Quality Control at IONIS Pharmaceuticals, Inc.
Wen-Chin earned his Ph.D. in Pharmaceutical Science from the University of Southern California; M.S. in Industrial Pharmacy from St. John's University, New York; and B.S. in Pharmacy from Kaohsiung Medical College, Taiwan.
Mac Sriwongjanya, Ph.D., joined OEP in 2016 as a principal scientist and has been Head of Research and Development since late 2016. In this role, he oversees the development and expansion of OEP’s product pipeline, handles regulatory inquiries, and helps secure regulatory approval.
Since joining OEP, Mac has filed multiple ANDAs on Modified Release Oral Dosage forms focusing on higher technical barrier products, and has had 5 Paragraph IV (PIV) with First-to-File (FTF) status with the USFDA.
Mac has over twenty years of experience in R&D, Technical Services and Manufacturing. Prior to joining OEP, Mac served as Director of Pharmaceutical and Manufacturing at Osmotica Pharmaceuticals; Associate Director of Product Development at Actavis/Abrika Pharmaceuticals; and worked in research and development for Knoll Pharmaceuticals, and Andrx Pharmaceuticals.
Mac received his B.S. in Pharmacy from Chulalongkorn University, Thailand, and Ph.D. in Pharmaceutics from The University of Texas at Austin.
Elenor Mak serves as OEP Pharma’s Head of Business Development. In this role, she oversees sales, marketing and partnerships for the company’s U.S. Headquarters. She also sits on the board of various OEP Pharma venture investments.
Elenor spent 10+ years in various leadership and sales and marketing positions in Fortune 300 consumer products companies. Prior to OEP Pharma, Elenor co-founded a venture backed e-commerce company, where she grew the sales and business operations from concept to 20+ team members. She was previously National Sales Director for Avon Products, where she managed a 500+ field sales organization; and worked in investment banking at Salomon Smith Barney (now Citigroup Global Markets) in New York.
She holds a B.A. from Dartmouth College, and an M.B.A. from Harvard Business School.
Praveen Tyle, Ph.D., has been a member of the Board of Directors since 2010.
Dr. Tyle is Executive Vice President of Research and Development at Lexicon Pharmaceuticals. He was previously a member of the executive management team at Osmotica Pharmaceutical Corp., serving as President and Chief Executive Officer from 2013 to 2016, and as Executive Vice President and Chief Scientific Officer in 2012.
Prior to his service at Osmotica, Dr. Tyle held a series of leadership positions within the pharmaceutical industry, including Executive Vice President and Chief Science Officer for the United States Pharmacopeia; Senior Vice President and Global Head of Research and Development, and Business Development and Licensing at Novartis OTC; Corporate Senior Vice President of Global Research and Development, and Chief Scientific Officer at Bausch & Lomb, Inc.; and Vice President and Global Head of Pharmaceutical Sciences at Pharmacia Corporation.
He received his B. Pharm (honors) from the Indian Institute of Technology, Banaras Hindu University, and his Ph.D. in pharmaceutics and pharmaceutical chemistry from the Ohio State University.